Clinical trials: Ocular Melanoma
Uveal Melanoma
Vorinostat in Patients With Class 2 High Risk Uveal Melanoma
This proof-of-concept study will evaluate the ability of vorinostat to induce the transformation of Class 2 uveal melanoma cells into a cell phenotype that resembles normal melanocytes.
- Trial name
- NCT03022565
- Testing
- Vorinostat
- Sponsor
- University of Miami
Cancer
Laboratory Assay in Determining Cancer Resistance in Patients With Metastatic Cancer and in Healthy Participants
RATIONALE: Studying samples of blood and tissue in the laboratory from patients with cancer and from healthy participants may help doctors learn more about cancer.
- Trial name
- NCT00899496
- Testing
- immunological diagnostic method, physiologic testing
- Where
- United States
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Wake Forest University Health Sciences
Uveal Melanoma
Prospective Registration Of Patient Data and Quality of Life in Eye Melanoma Patients
PROQEM is a prospective cohort study among patients diagnosed with uveal melanoma to assess quality of life before and in the first five years after treatment.
- Trial name
- PROQEM (NCT05377957)
- Testing
- Quality of life questionnaires, Discrete choice experiment, Shared decision-making analysis
- Where
- Netherlands
- Volunteers
- 500 people
- Sponsor
- Leiden University Medical Center
Uveal Melanoma
Hypofractionated Stereotactic Linear Accelerator Radiotherapy of Uveal Melanoma
The purpose of this study is to assess the safety and efficacy of hypofractionated stereotactic LINAC radiotherapy with 10 fractions at 6 Gy per fraction at the 80% isodose for the planning target volume (PTV) in patients with…
- Trial name
- NCT00872391
- Testing
- Hypofractionated linear accelerator radiotherapy
- Where
- Austria
- Volunteers
- 155 people
- Sponsor
- Medical University of Vienna
Intraocular Melanoma, Melanoma (Skin)
Temozolomide and Interferon Alfa in Treating Patients With Stage III or Stage IV Melanoma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Interferon alfa may interfere with the growth of cancer cells.
- Trial name
- NCT00027742
- Testing
- pegylated interferon alfa, temozolomide
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Recurrent Uveal Melanoma, Stage IV Uveal Melanoma AJCC v7
Trametinib With or Without GSK2141795 in Treating Patients With Metastatic Uveal Melanoma
This randomized phase II trial studies how well trametinib with or without Akt inhibitor GSK2141795 (GSK2141795) works in treating patients with uveal melanoma that has spread to other parts of the body (metastatic).
- Trial name
- NCT01979523
- Testing
- Laboratory Biomarker Analysis, Pharmacological Study, Trametinib
- Where
- 7 sites in United States, France and 1 more
- Volunteers
- 42 people
- Sponsor
- National Cancer Institute (NCI)
Uveal Melanoma
Dendritic Cells Plus Autologous Tumor RNA in Uveal Melanoma
Patients suffering from uveal melanoma (typed positive for monosomy 3 and without evidence for metastases) will be vaccinated over a period of 2 years with Dendritic Cell loaded with autologous Tumor RNA.
- Trial name
- NCT01983748
- Testing
- Autologous Dendritic Cells loaded with autologous Tumor RNA
- Where
- 8 sites in Germany
- Volunteers
- 200 people
- Sponsor
- University Hospital Erlangen
Uveal Melanoma
A Phase Ib/II Study of AEB071 and MEK162 in Adult Patients With Metastatic Uveal Melanoma
A phase Ib dose-escalation study of the AEB071 and MEK162 combination in adult patients with confirmed metastatic uveal melanoma.
- Trial name
- NCT01801358
- Testing
- AEB071, MEK162
- Where
- 7 sites in United States, France and 4 more
- Volunteers
- 38 people
- Sponsor
- Array Biopharma, now a wholly owned subsidiary of Pfizer
Cutaneous Melanoma, Mucosal Melanoma
Neoadjuvant and Adjuvant Checkpoint Blockade
This randomized phase II trial studies how well nivolumab with or without ipilimumab or relatlimab before surgery works in treating patients with stage IIIB-IV melanoma that can be removed by surgery.
- Conditions
- Cutaneous Melanoma, Mucosal Melanoma, Ocular Melanoma, Stage III Acral Lentiginous Melanoma AJCC v7
- Trial name
- NCT02519322
- Testing
- Ipilimumab, Laboratory Biomarker Analysis, Nivolumab
- Where
- 2 sites in United States
- Volunteers
- 53 people
- Sponsor
- M.D. Anderson Cancer Center
Uveal Melanoma, Metastatic
Targeted Alpha Particle Radiotherapy for Metastatic Uveal Melanoma
The primary aim of the study is to establish the maximum-tolerated dose (MTD) of 225Ac-MTI-201 in participants with metastatic uveal melanoma.
- Trial name
- NCT05496686
- Testing
- 4.7 microCi 225Ac-MTI-201, 9.5 microCi of 225Ac-MTI-201, 19 microCi of 225Ac-MTI-201
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Modulation Therapeutics, Inc.
Nevus, Racial Melanosis
In Vivo Confocal Microscopy Study of Pigmented Conjunctival Lesions
This study aims to validate the use of laser in vivo confocal microscopy as an early diagnostic and differentiation tool of pigmented conjunctival lesions, evaluate the efficacy of in vivo confocal microscopy for follow-up (as a…
- Conditions
- Nevus, Racial Melanosis, Primary Acquired Melanosis, Conjunctival Malignant Melanoma
- Trial name
- NCT01993654
- Testing
- HRT III with Non-Contact Cornea Rostock Module
- Where
- 3 sites in United States
- Volunteers
- 17 people
- Sponsor
- Massachusetts Eye and Ear Infirmary
Uveal Melanoma
Psychoeducation for Uveal Melanoma
This clinical trial evaluates a video-based psychoeducational intervention for patients with uveal melanoma. Uveal melanoma (UM) is a rare intraocular cancer.
- Trial name
- NCT06075589
- Testing
- Education for Intervention, Best Practice
- Where
- United States
- Volunteers
- 108 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Uveal Melanoma, Cutaneous Melanoma
Frequency and Clinical Phenotype of BAP1 Hereditary Predisposition Syndrome
This research will have a significant impact on the overall management of those cancer patients and their family members who are at risk for hereditary cancer due to germline inactivation of BAP1.
- Conditions
- Uveal Melanoma, Cutaneous Melanoma, BAP1 Gene Mutation, Renal Cell Carcinoma
- Trial name
- NCT04792463
- Where
- United States
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Mohamed Abdel-Rahman
Melanoma (Skin), Intraocular Melanoma
Safety and Immunogenicity of a Melanoma DNA Vaccine Delivered by Electroporation
The purpose of this study is to evaluate the safety and immunogenicity of a DNA vaccine encoding a melanosomal antigen in melanoma patients at risk for disease progression or recurrence.
- Trial name
- NCT00471133
- Testing
- Xenogeneic Tyrosinase DNA Vaccine, TriGrid Delivery System for Intramuscular Electroporation
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Ichor Medical Systems Incorporated
Exudative Retinal Detachment, Uveal Melanoma
TTT Versus TTT and Triamcinolone to Decrease Exudation in Choroidal Melanoma After Proton Beam Therapy
Proton beam therapy is a safe irradiation modality for choroidal melanoma. But often after irradiation the exudation increases resulting in an exudative retinal detachment requiring vitreoretinal surgery.
- Trial name
- NCT02379000
- Testing
- Triamcinolone Acetonide, Transpupillary thermotherapy
- Where
- Germany
- Volunteers
- 50 people
- Sponsor
- Charite University, Berlin, Germany
Cancer
Imatinib Mesylate And Cyclophosphamide In Metronomic Administration: Dose Escalation Study Of Imatinib Mesylate
The purpose of this study is to determine the maximum tolerated dose of imatinib mesylate, given in association with a fixed dose of cyclophosphamide (50 mg bid).
- Trial name
- PALANGI3 (NCT01046487)
- Testing
- Imatinib mesylate, Cyclophosphamide (Dosing level 1 ), Imatinib mesylate, Cyclophosphamide (Dosing level 2), Imatinib mesylate, Cyclophosphamide (Dosing level 3)
- Where
- 3 sites in France
- Volunteers
- 26 people
- Sponsor
- Centre Oscar Lambret
Solid Tumor, Adult
Study Assessing MTD, Safety, Tolerability, PK and Anti-tumor Effects of LNS8801alone and With Pembrolizumab
This Phase 1/2, first-in-human, open-label, multicenter study follows a 3+3 ascending dose escalation design to determine the MTD/RP2D and to characterize the safety, tolerability, PK, and antitumor effects of LNS8801 alone and…
- Trial name
- NCT04130516
- Testing
- LNS8801 -Small molecule, orally bioavailable, selective agonist of GPER, Pembrolizumab - anti-PD-1 antibody
- Where
- 10 sites in United States
- Volunteers
- 200 people
- Sponsor
- Linnaeus Therapeutics, Inc.
Uveal Melanoma, Ocular Melanoma
Study in Subjects With Small Primary Choroidal Melanoma
The primary objective is to assess the safety, immunogenicity and efficacy of one of three dose levels and repeat dose regimens of Light-activated AU-011 and one or two laser applications for the treatment of subjects with…
- Conditions
- Uveal Melanoma, Ocular Melanoma, Choroidal Melanoma
- Trial name
- NCT03052127
- Testing
- Light-activated AU-011, Laser Activation
- Where
- 13 sites in United States
- Volunteers
- 57 people
- Sponsor
- Aura Biosciences
Metastatic Uveal Melanoma, Stage IV Uveal Melanoma AJCC v7
Nivolumab and Ipilimumab in Treating Patients With Metastatic Uveal Melanoma
This phase II trial studies how well nivolumab and ipilimumab work in treating patients with uveal melanoma that has spread to other places in the body (metastatic).
- Trial name
- NCT01585194
- Testing
- Ipilimumab, Laboratory Biomarker Analysis, Nivolumab
- Where
- United States
- Volunteers
- 67 people
- Sponsor
- M.D. Anderson Cancer Center
106 Ruthenium Plaque Brachytherapy, Uveal Melanoma
Uveal Melanoma and Brachytheraphy: Long-term Outcomes.
This study investigated the visual and anatomical outcomes, tumor control, tumor recurrence, distant metastasis and cancer free survival in patients affected by uveal melanoma and undergoing Ru-106 plaque brachytherapy between…
- Trial name
- NCT04577742
- Testing
- 106 Ruthenium plaque brachytherapy
- Where
- Italy
- Volunteers
- 350 people
- Sponsor
- Federico II University